Primary study · included by 1 review

Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial.

Carlander 2025 (MESRIX-III 12-month follow-up) · Fenger Carlander Amanda-Louise, Jakobsen Kathrine Kronberg, Todsen Tobias, et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

Included by

Treatment of Xerostomia with Mesenchymal Stem Cells - A Systematic Review and Meta-Analysis of Clinical Trials.

Non-Cochrane · intervention · 2026 · cited as Carlander 2025 (MESRIX-III 12-month follow-up) · Results, Table 1; reference 36; ROB-ME supplement

Outcome this study informs	Pooled effect	Evidence	Certainty
Unstimulated whole salivary flow rate (UWS) Mesenchymal stem cell (MSC) injection into the salivary glands vs Placebo (saline, saline with albumin, or DMSO) · Long term (6 months to 2 years; latest time point, 12 months)	MD 0.01 [-0.02, 0.05]	2 studies · 150 participants	GRADE not reported

1 including review in total.